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Abstract 
Breast cancer risk is a common indication for referral to clinical genetics services. UK National 
Institute of Health and Care Excellence (NICE) guidelines use family history (FH) to stratify by 
10-year risk of breast cancer from age 40. Patients are stratified into population risk (PR, 10-year
risk <3%), moderate (MR, 3-8%) and high risk (HR, >8%). Women at increased risk are offered 
screening at or prior to age 40. To assess the clinical effectiveness of current risk stratification, FH 
data was obtained for all unaffected women with a FH of breast cancer aged <50, referred to cancer 
genetics from 2000-2010. Patients were risk stratified by NICE criteria, identifying patients who 
subsequently developed breast cancer. 1,409 women had 15,414 patient-years of follow up. 30 
invasive breast cancers developed, 13 in MR and 13 in HR women. Kaplan-Meier analysis 
demonstrated no significant difference in rate of breast cancer development between PR and MR 
women from ages 40-49 (Log rank p=0.431). There was a significant difference between ages 40-
49 years between PR and HR women (p=0.036), but not on exclusion of BRCA mutation carriers 
(p=0.136). NICE absolute 10-year risk thresholds between ages 40-49 were not met in any risk 
group, when risk was estimated using the guidelines (PR=0.82%, MR=1.68%, HR=3.56%). Our 
data suggests that improved criteria are required for risk assessment prior to age 50 and screening 
resources may be best focussed on those with highly penetrant mutations in cancer risk genes. 
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 Introduction 
Familial clustering of breast cancer is a common indication for referral to clinical genetics services. 
Whilst shared environmental factors contribute, they do not fully explain the risk, and genetic 
predisposition is thought to be a major factor. This can be due to rare, highly penetrant mutations, 
or multiple low penetrance variants (1,2). Risk assessment includes variant analysis for known 
cancer risk genes where appropriate, or assessment by family history (FH). The UK National 
Institute of Health and Care Excellence (NICE) provide guidance for classification and 
management of people with a FH of breast cancer (CG164) (3). Patients are stratified according to 
FH into near population risk (PR), moderate risk (MR) and high risk (HR) based on percentage 
lifetime risk and 10-year risk from age 40. Risk stratification uses empirical criteria provided 
(shown in Table 1), or other models such as the Breast and Ovarian Analysis of Disease Incidence 
and Carrier Estimation Algorithm (BOADICEA), a computer program that is used to calculate the 
risks of breast and ovarian cancer in women based on their family history (4). NICE recommends 
additional screening for women at MR and HR, as seen in Table 1, in the form of mammograms 
or MRI. This is of relevance for younger women who are not yet enrolled in the UK National 
Breast Screening Programme (NBSP), which offers 3-yearly mammograms to all women aged 50-
70. To our knowledge, there has been no attempt to validate the empirical NICE criteria in women 
attending clinical genetics services regarding their breast cancer risk. 
Subjects and Methods 
Female patients referred to clinical genetics services for breast cancer risk from 2000-2010 were 
included in the study. Patients were aged under 50 at initial consultation, with no personal history 
of breast and/or ovarian cancer. FH information was collected from clinical genetics services 
records. BRCA (referring to both BRCA1 and BRCA2) mutation carriers were identified through 
the national BRCA testing service. Women who went on to develop breast cancer were identified 
by linkage to pathology records. 
All women were risk categorised into PR, MR and HR as outlined in the NICE guidelines 
(3). NICE guidelines do not state that affected relatives must be from the same side of the family. 
However, it is acknowledged that many clinicians interpret the guidelines this way. Therefore, all 
analyses were performed based on a risk categorisation which 1) did not assume and 2) assumed 
same-side FH as necessary to meet risk criteria. The result of BRCA testing was also considered 
for appropriate risk categorisation. This was time intensive with each case taking between 5-15 
minutes for risk assignment. As this was done retrospectively using clinical notes, time taken for 
clinical consultation and confirmation of diagnoses of affected family members is not included.  
Percentage 10-year risk was calculated for each risk category and for BRCA mutation 
carriers, for ages 40-49 and ages 50-59 years inclusive. Incidence of breast cancer per patient year 
of follow up within each group was calculated, and extrapolated to give the 10-year absolute breast 
cancer risk. Kaplan-Meier Survival Analysis (KMSA) was used to assess the rate of breast cancer 
development across different risk categories and age ranges. Patients were censored at completed 
time of follow up or at breast cancer diagnosis. The HR group was analysed both including and 
excluding BRCA carriers.  
Results  
In total, 1,409 patients were eligible for inclusion with a total of 15,414 patient years of follow up. 
Using both sides of the FH to calculate risk, 505 women were PR (35.8%), 522 MR (37%) and 
382 HR (27.1%), including 12 BRCA1 and 10 BRCA2 carriers. Using only a same-side FH, there 
were 554 (39.3%) PR, 490 (34.8%) MR and 365 (25.9%) HR women. 
30 women developed an invasive cancer prior to May 2016. The frequency and percentage 
10-year absolute risk are shown in Table 2. Not assuming a same-side FH, the highest absolute 
risk between the ages of 40-49 was in the HR group, both including (3.56% (3.34-3.80%) and 
excluding BRCA carriers (2.49% (2.28-2.70%). From ages 50-59, the MR group had the highest 
percentage absolute risk, at 7.05% (6.78-7.31%).  
Between ages 40-49, none of the groups met the 10-year risk suggested by NICE 
guidelines. Assuming a same-side FH, a similar pattern of absolute risk is seen, with no group 
reaching the screening threshold suggested by NICE.  
Table 3 shows the results of KMSA. Not assuming same-side FH there is no significant 
difference in rate of breast cancer development between PR and MR group from 40-49 (p=0.431). 
A risk difference between these two groups emerges after the age of 50 (p=0.037). When same-
side FH is assumed, there is no significant difference in breast cancer rates between PR and MR 
group overall (p=0.134) or across any age range (<39 years p=0.283, 40-49 years p=0.791, 50-59 
years p=0.11).  
Both not assuming, and assuming same-side FH, there is a difference in breast cancer rates 
between the PR and HR women from 40-49 (p=0.036 and p=0.042 respectively) However, this 
significance is lost on exclusion of BRCA carriers (p=0.136 and p=0.171 respectively). There is 
no significant difference in rate of breast cancer between these groups from the ages of 50-59 not 
assuming or assuming same-side FH (p=0.149 and p=0.063).  
The MR and HR group combined were compared with the PR group to try and detect a 
significantly increased rate of breast cancer in women deemed at any increased risk. Not assuming 
same-side FH, the MR/HR group (excluding BRCA carriers) had a significantly increased rate of 
breast cancer from 50-59 years (p=0.049). There was no detectable difference in breast cancer 
rates between MR and HR women at any time.   
 
Discussion 
Before the age of 50, neither the MR or HR groups have a risk that reached the suggested NICE 
10-year threshold. KMSA showed the rate of breast cancer development under the age of 50 to be 
significantly greater for those with a BRCA mutation but, crucially, not for other MR or HR 
women in the cohort compared to the PR group.  
Our study has used a real clinical cohort, based on routine clinical practice for patients 
referred over a 10-year period. In this context, empirical NICE risk criteria do not appear to achieve 
effective risk stratification of those without a highly penetrant mutation before the age of 50. In 
the MR group, there was a detectable increase in cancer risk after the age of 50, however, additional 
screening is not mandated for this group. When interpreted as requiring a same-sided FH, empirical 
criteria fail to detect this difference. 
It is recognised that the moderately increased risk of breast cancer observed in some 
families may be due to a multifactorial, polygenic risk model. The greater ability of the guidance 
to identify at-risk women when both sides of a FH are used in risk estimation, may reflect this 
model of inheritance, with risk alleles being transmitted from both sides of the family. Future 
routine clinical practice is likely to require the analysis of genetic variants contributing to 
polygenic risk to achieve better performing risk estimation models. This is currently under 
investigation (5, 6).   
NICE guidelines do suggest use of other methods of risk stratification, specifically 
BOADICEA (3). There is evidence that other methods such as BOADICEA may be effective in 
risk stratification (7), although there is no direct published comparison with NICE empirical 
criteria.  
This study has used a simple methodology to assess current clinical practice in UK cancer 
genetics.  Of 1,409 patients being screening over a 16-year period, 30 developed invasive breast 
cancer. In this cohort, the ability of the current guidance to identify at risk women, once highly 
penetrant mutations are excluded, is poor. Though we have a moderate cohort size, we feel that 
these results are important and should encourage further investigation of the effectiveness of these 
national guidelines. It would appear beneficial to refine risk stratification methods to focus 
resources on women who will benefit most from early screening.  
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Moderate Risk High Risk (including BRCA mutation carriers)
NICE criteria
- One FDR diagnosed with 
breast cancer at younger than 
age 40 years
or
- Two first-degree or SDRs 
diagnosed with breast cancer at 
an average age of older than 50 
years
or
- Three first-degree or SDRs 
diagnosed with breast cancer at 
an average age of older than 60 
years
At least the following female breast cancers only in the family:
- Two first-degree or SDRs diagnosed with breast cancer at younger 
than an average age of 50 years (at least one must be a FDR)
or
- Three first-degree or SDRs diagnosed with breast cancer at 
younger than an average age of 60 years (at least one must be a 
FDR )
or
- Four relatives diagnosed with breast cancer at any age (at least one 
must be a FDR)
or
Families containing one relative with ovarian cancer at any age 
and, on the same side of the family:
- One FDR (including the relative with ovarian cancer) or SDR 
diagnosed with breast cancer at younger than age 50 years.
or
- Two first-degree or SDRs diagnosed with breast cancer at younger 
than an average age of 60 years.
or
- Another ovarian cancer at any age.
or
Families affected by bilateral cancer (each breast cancer has the 
same count value as one relative):
- One FDR with cancer diagnosed in both breasts at younger than 
an average age 50 years.
or
- One first-degree or SDR diagnosed with bilateral cancer and one 
first or SDR diagnosed with breast cancer at younger than an 
average age 60 years.
or
Families containing male breast cancer at any age and, on the 
same side of the family, at least:
- One first-degree or SDR diagnosed with breast cancer at younger 
than age 50 years.
or
- Two first-degree or SDRs diagnosed with breast cancer at younger 
than an average age of 60 years.
Mammographic Surveillance
Offer annually to women:
- aged 40–49 years
Consider annually for women:
-aged 50-59 years
Offer annually to women:
- Aged 40–59 years at high risk of breast cancer but with a 30% or 
lower probability of being a BRCA  or TP53  carrier
- Aged 40–59 years who have not had genetic testing but have a 
greater than 30% probability of being a BRCA  carrier
- Aged 40–69 years with a known BRCA1  or BRCA2  mutation
Offer as part of the population screening programme to women:
- Aged 70 years and over with a known BRCA1  or BRCA2 
mutation
Consider annually for women:
- Aged 30–39 years at high risk of breast cancer but with a 30% or 
lower probability of being a BRCA  carrier
- Aged 30–39 years who have not had genetic testing but have a 
greater than 30% probability of being a BRCA  carrier
- Aged 30–39 years with a known BRCA1  or BRCA2  mutation
MRI surveillance Do not offer at any age
Offer annually to women:
- Aged 30–49 years who have not had genetic testing but have a 
greater than 30% probability of being a BRCA  carrier
- Aged 30–49 years with a known BRCA1 or BRCA2  mutation
Risk-reducing mastectomy Do not offer
-Should be raised as a risk-reducing strategy option with all women 
at high risk
-Women considering this Should have specialist genetic counselling
Risk-reducing oopherectomy Do not offer Information should be provided 
Table 1. NICE risk criteria and interventions
40-49 years 50-59 years 40-49 years 50-59 years
2 2 3 3
0.82% (0.72-0.94%) 1.61% (1.42-1.83%) 1.11% (0.10-1.23%) 2.23% (2.02-2.47%)
4 8 3 7
1.68% (1.53-1.83%) 7.05% (6.78-7.31%) 1.37% (1.23-1.52%) 6.47% (6.19-6.75%)
4 4 4 4
2.49% (2.28-2.70%) 5.28% (4.93-5.64%) 2.62% (2.40-2.84%) 5.62% (5.26-5.99%)
2 1 2 1
26.67% (17.98-37.63%) 52.63% (31.71-72.67%) 26.67% (17.98-37.63%) 52.63% (31.71-72.67%)
6 5 6 5
3.56% (3.34-3.80%) 6.44% (6.10-6.78%) 3.74% (3.51-3.98%) 6.84% (6.50-7.18%)
High Risk (including BRCA carriers)
BRCA carriers
High Risk (excluding BRCA carriers)
Moderate Risk
Table 2. Frequency and absolute risk of breast cancer by NICE risk category
Number of invasive cancers 
Population risk
Risk categorised using both sides of FH Risk categorised using only one side of FH
Number of invasive cancers 
% 10-year absolute risk (95% CI) % 10-year absolute risk (95% CI)
Total follow up time <39 years 40-49 years 50-59 years Total follow up time <39 years 40-49 years 50-59 years
Population & moderate 0.048 0.341 0.431 0.037 0.134 0.283 0.791 0.11
Population & high 0.003 0.091 0.036 0.149 0.005 0.328 0.042 0.063
Population & high (BRCA  carriers excluded) 0.019 0.085 0.136 0.145 0.027 0.317 0.171 0.131
Moderate & high 0.274 0.328 0.183 0.581 0.218 0.995 0.111 0.795
Moderate & high (BRCA  carriers excluded) 0.644 0.299 0.499 0.598 0.505 0.963 0.334 0.942
Population & moderate/high 0.011 0.216 0.134 0.05 0.022 0.298 0.206 0.069
Population & moderate/high (BRCA  carriers excluded) 0.024 0.217 0.241 0.049 0.049 0.292 0.383 0.093
KM Log-Rank (p -value)
Same-side FH not assumed Same-side FH assumed
KM Log-Rank (p -value)
Table 3. Kaplan-Meier analysis of rate of breast cancer diagnosis comparing NICE risk categories by age range
